Objective: The aim of the present study was to screen and to identify the cytotoxic compound from the leaves of Kigelia pinnata. Materials and Methods: Dry leaf powder of K. pinnata was extracted with chloroform and the extract was tested for anticancer cytotoxic activity by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2h-tetrazolium bromide (MTT) assay in human colorectal carcinoma (HCT-116) cells. Crude extract was purified by silica gel column chromatography and the active fraction was identified by using spectroscopic techniques such as nuclear magnetic resonance, fourier transform-infrared spectroscopy and gas chromatography-mass spectrometry analysis. The identified compound was docked with cancer drug target protein, DNA topoisomerase-I using AutoDock4. Results: Crude extract showed significant anticancer cytotoxic activity with IC 50 value of 80 g mLG 1 . The GC-MS chromatogram showed the presence of more than 15 different phytochemical compounds. The active fraction of the crude was identified as N-hexadecanoic acid with a molecular weight 256.42 Da and molecular formula C 16 H 32 O 2 . Molecular docking analysis showed that N-hexadecanoic acid has high affinity interaction with DNA topoisomerase-I with a free binding energy -6.71 kcal molG 1 . The N-hexadecanoic acid demonstrated significant IC 50 value of 0.8 g mLG 1 against HCT-116 cells. Conclusion: Based on the results of docking studies, it is proposed that the observed cytotoxic activity of N-hexadecanoic acid is due to its interaction with DNA topoisomerase-I and itcould be explored further for its anticancer cytotoxic potential with other cancer drug target proteins.
No takes yet. Share an insight, caveat, or question.
Ravi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: